Clinical Trial Update: Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil [Phase 4]

View source ↗

Summary

Phase 4 trial update studying whether olfactory deficits in mild cognitive impairment predict improved cognition with donepezil; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Aricept (Donepezil)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Mild Cognitive Impairment | Phase 4 | Status: COMPLETED | Results posted: 2018-03-13